Phase 2 Start
IOVA: Phase 2 Start: A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Par
September 1, 2026 · lifileucel. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 1, 2026
- Company
- IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
- Drug
- lifileucel
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Par
- Drug
- lifileucel
- Indication
- Sarcoma; Advanced Soft Tissue Sarcoma; Soft Tissue Sarcoma (STS)